1 y distinct characteristics, depending on the underlying disease.
2 ce of contaminating pathogens, endotoxin, or underlying disease.
3 fection or bleeding above the rate caused by underlying disease.
4 nd menopause (age >/=50 years) regardless of underlying disease.
5 nvolvement is the first manifestation of the underlying disease.
6 with a genetic basis than for those with no underlying disease.
7 8 infection might understate the severity of underlying disease.
8 ut treatment was specified as death from the underlying disease.
9 ty; however, it may be a marker of a serious underlying disease.
10 7), in addition to age, gender mismatch, and underlying disease.
11 otentially are connected to an infectious or underlying disease.
12 d potentially ameliorate the symptoms of the underlying disease.
13 an add substantially to the morbidity of the underlying disease.
14 e been reported, usually in association with underlying disease.
15 tality due to complications related to their underlying disease.
16 okine receptors may, on occasion, exacerbate underlying disease.
17 nintentional weight loss due to undiagnosed, underlying disease.
18 k of death from VOD against the risks of the underlying disease.
19 rachnoiditis, which were often caused by the underlying disease.
20 ations of infection often mimic those of the underlying disease.
21 leroderma patients could be secondary to the underlying disease.
22 tive capacity, might be perturbed due to the underlying disease.
23 aftment and was effective at eradicating the underlying disease.
24 stresses of pulmonary exacerbations of their underlying disease.
25 itical role of biomarkers for diagnosing the underlying disease.
26 ndings and outcomes according to the type of underlying disease.
27 trathecal IgG synthesis independently of the underlying disease.
28 ontrol group (n = 115, 2007-2008) with equal underlying disease.
29 derstand and reveal the molecular mechanisms underlying disease.
30 utilizing language phenotype as a marker of underlying disease.
31 for the analysis of the molecular mechanisms underlying disease.
32 acy of these techniques for the detection of underlying disease.
33 tentially teratogenic medications and severe underlying disease.
34 -risk cohort were alive and cured from their underlying disease.
35 sus have been critical for understanding the underlying disease.
36 ospital admission, advancing age, and severe underlying disease.
37 omise of reducing lung damage related to the underlying disease.
38 biases appear to vary with the nature of the underlying disease.
39 ng of inquiry influence these assessments of underlying disease.
40 risk group, HSC source, donor type, age, and underlying diseases.
41 All patients had significant underlying diseases.
42 ften precipitates aggressive assessments for underlying diseases.
43 from 17 days to 16 yrs, and they had various underlying diseases.
44 le who are most vulnerable because of age or underlying diseases.
45 ntibodies to GM-CSF or is secondary to other underlying diseases.
46 iomyopathy and the other with lung cancer as underlying diseases.
47 Half of the cases had underlying disease (49.0%), and over one-fifth (22.9%) w
48 There were four deaths owing to underlying disease 6-21 months after the procedures.
49 Bone marrow histology reflects underlying disease activity in ET but many morphological
50 lving T2-weighted lesions, which may reflect underlying disease activity more sensitively.
51 Demographic characteristics; underlying disease; Acute Physiology and Chronic Health
52 Patient-related risk factors include underlying disease, age, gender, comedications, nutritio
53 ffects of stem cell transplant (SCT) status, underlying disease, age, sex, ethnicity, and antibody st
54 he context and to assess the severity of the underlying disease alone to predict survival time and qu
55 h those from persons without or with another underlying disease, although one C. noeformans var. gatt
56 ed events were associated with the patient's underlying disease and age, the number of leukocytes in
57 scular disease, rather than being related as underlying disease and complication, share common geneti
58 end point that is an accurate measure of the underlying disease and is not confounded by potential sy
59 Depending on the underlying disease and its associated initial CMV risk,
60 oping these adverse events is related to the underlying disease and its treatment with cytotoxic drug
61 Depending on the underlying disease and mechanisms, eosinophil infiltrati
62 closely related to operative techniques and underlying disease and not to aspirin treatment.
63 Breast cancer as an underlying disease and pulmonary edema as a complication
64 This risk varies with the nature of the underlying disease and seems to be greatest for membrano
65 in mortality was explained by differences in underlying disease and the site of infection.
66 Two patients died before day 100 from underlying disease and viral infection, respectively (da
67 visceral transplantation cured the patient's underlying disease and was lifesaving.
68 renal limitations (CRLimit) have more severe underlying disease and worse outcome.
69 in unselected patients with a broad range of underlying diseases and conditions has not been studied.
70 or unselected patients with a broad range of underlying diseases and conditions.
71 last year, both in the understanding of the underlying diseases and in improvements in the managemen
72 erse multiresistant organisms: advanced age; underlying diseases and severity of illness; inter-insti
73 effective treatment of both the symptoms and underlying disease, and appropriate surveillance for the
74 well as factors specific to the patient, the underlying disease, and its treatment.
75 ibody is expensive, limited to children with underlying disease, and not practical for general use.
76 t itself, to its mode of administration, the underlying disease, and patient characteristics.
77 e for young children, three for persons with underlying disease, and two for pregnant women.
78 Patients were stratified for age, sex, and underlying diseases, and bacteria were identified by 16S
79 in vivo and to identify molecular mechanisms underlying disease as a result of its mutation.
80 rhythms as a result of the severity of their underlying diseases as well as the intensive care unit e
81 haled nitric oxide therapy is related to the underlying disease associated with persistent pulmonary
82 re increasingly encountered in children with underlying diseases associated with immunosuppression, i
83 ngth of the T cell stimulus and corrects the underlying disease-associated cytokine skew in T cell-me
84 raction and have implications for mechanisms underlying disease associations of DQ2.
85 g systems-level analyses to reveal processes underlying disease associations.
86 Underlying disease, baseline liver impairment, and conco
87 With the goal of downstaging underlying disease before alloSCT, AZA alone led to outc
88 With the assumption of a constant underlying disease burden, only 8 of the 122 additional
89 s, and cell replacement therapy provided the underlying disease-causing mutation can be corrected.
90 es using patient-specific iPSCs, even if the underlying disease-causing mutation is not expressed in
91 is is partly determined by the nature of the underlying disease, comorbidities and other immunosuppre
92 Clinical variables, including underlying disease, conditioning regimen, stem cell dono
93 eters were similar with respect to age, sex, underlying diseases, degree of immunosuppression, therap
94 f gut dysfunction related to the severity of underlying disease determines the duration of PN and the
95 The mechanisms underlying disease development and progression are await
96 Underlying disease diagnosis (lymphoid > myeloid) and re
97 clinical state, suggesting persistence of an underlying disease diathesis between episodes.
98 For patients >40 days after transplant, age, underlying disease, donor type, graft-versus-host diseas
99 re similar with regard to age, race, gender, underlying disease, donor type, incidence of delayed gra
100 or patients within 40 days after transplant, underlying disease, donor type, season, and transplant o
101 This proinflammatory response may exacerbate underlying disease during P. aeruginosa infections.
102 ical variables are often confounded with the underlying disease effects, which further hampers accura
103 Despite this, the mechanisms underlying disease emergence are still not fully underst
104 ovided that the model correctly reflects the underlying disease etiology.
105 rological, and/or parasitological parameters underlying disease exacerbation in HIV-malaria coinfecte
106 could allow us to identify specific pathways underlying disease; explain disease heterogeneity by gro
107 terplay of genetic and environmental factors underlying disease expression.
108 < 0.001); however, after allogeneic SCT, the underlying diseases had little effect, except for multip
109 han in men (0.50% of 4,161) (P < 0.001), and underlying diseases had no effect in women.
110 se paraclinical tests aid in identifying the underlying disease has relevance to the practising clini
111 However, the causal variants and haplotypes underlying disease have not yet been identified.
112 st registration for liver transplantation by underlying disease (HBV and HCV infection and other) and
113 gh rate of suboptimal nutrition or potential underlying disease impairment.
114 ty, ostensibly caused by the severity of the underlying disease in many patients.
115 of treatments and progression/regression of underlying disease in neonates managed with HFOV.
116 mortality, adjusted for the severity of the underlying disease, in patients with GI bleeding.
117 nsidered to result from the pathology of the underlying disease, increasing evidence now indicates th
118 mortality independent of the severity of the underlying disease is unclear.
119 ems likely that the bulk of genetic variance underlying diseases is due to loci where susceptibility
120 is requires careful assessment over time for underlying diseases like systemic lupus erythematosus, h
121 duals (5 males and 5 females) and mapped the underlying disease locus to chromosome 16p12-p13 (LOD sc
122 cranial aneurysm and map the location of the underlying disease locus.
123 Despite extreme underlying disease, long-term survival is excellent in p
124 bservation of patients for evidence that the underlying disease may complicate their pulmonary status
125 Physician monitoring of the infection and underlying diseases may not be as frequent despite the n
126 4 may represent physical determinants of the underlying disease mechanism in inherited focal segmenta
127 n made, a comprehensive understanding of the underlying disease mechanism is still lacking.
128 temic lupus erythematosus or inherent to the underlying disease mechanism may contribute to each of t
129 h there are few therapeutics that affect the underlying disease mechanism.
130 distinct class of patients with a different underlying disease mechanism.
131 pharmacokinetic; 2) pharmacodynamic; and 3) underlying disease mechanism.
132 for providing probabilistic estimates of the underlying disease mechanism.
133 A chief impediment in understanding the underlying disease mechanisms and developing treatment s
134 Although underlying disease mechanisms are not well understood, m
135 genetic variation have been documented, the underlying disease mechanisms remain poorly elucidated.
136 Although the underlying disease mechanisms remain unknown, glial cell
137 ic information with limited clarification of underlying disease mechanisms.
138 gy of the disease and tools for studying the underlying disease mechanisms.
139 e routine toxicity testing and evaluation of underlying disease mechanisms.
140 n is important for a better understanding of underlying disease mechanisms.
141 ich food is ingested orally; gut absorption; underlying disease; medication adversely affecting bone,
142 nd, in addition, allows investigation of the underlying disease models, including interactions.
143 The underlying diseases of the patients were lymphocytic leu
144 Because of the minimal adverse effect of the underlying disease on cells of the newborn, the relative
145 ustments are made for effects of smoking and underlying disease, optimal weights are below average in
146 , with most adverse events attributed to the underlying disease or concomitant chemotherapy.
147 ria and treatment strategies tailored to the underlying disease or genetic context are needed and wil
148 For patients in whom no underlying disease or hypereosinophilic syndrome is foun
149 patients were not withdrawn due to return of underlying disease or rejection episodes.
150 y to atherosclerosis development or reflects underlying disease or risk factors remains unclear.
151 herited or acquired, secondary to either the underlying disease or selected therapeutic interventions
152 atients with varying degrees of PSS based on underlying disease or the presence of a surgical shunt o
153 f the work-up to facilitate detection of any underlying disease or to establish a limited differentia
154 Damage due to underlying disease or treatment highlights the need for
155 95% CI, 1.4-20.9; P = .016), a rapidly fatal underlying disease (OR 4.4; 95% CI, 1.5-12.6; P = .006),
156 xin might be the principal virulence factors underlying disease organotropism.
157 ods for defining and staging the most likely underlying disease (osteoarthritis), clinically practica
158 nsplanted for HCV cirrhosis and eight for an underlying disease other than HCV.
159 atients with HIV/AIDS than in adults with no underlying disease (P<.05, vs. serotype 4), even when TM
160 The mechanisms underlying disease pathogenesis are unclear, and there i
161 ent of SARS, a thorough understanding of the underlying disease pathogenesis has been hampered by the
162 in is largely unknown, the molecular defects underlying disease pathogenesis remain obscure.
163 e latency, onset and progression, mechanisms underlying disease pathogenesis, and responses to new an
164 of understanding of the molecular mechanisms underlying disease pathogenesis, particularly in non-CNS
165 rkinje cell dendritic morphology potentially underlying disease pathogenesis.
166 ature and summarize the molecular mechanisms underlying disease pathology and examine their potential
167 ich has largely defied mapping analysis, the underlying disease pathology, undamped neuronal signalin
168 al role in the study of molecular mechanisms underlying disease pathology.
169 new therapeutic strategies to interrupt the underlying disease pathways.
170 cal laboratory to identify sequence variants underlying disease phenotypes in patients.
171 portunity for identifying genes and pathways underlying disease phenotypes.
172 The association could be driven by underlying disease physiology or medications used to tre
173 than others, depending on the nature of the underlying disease physiology.
174 Geographic factors underlying diseased populations coupled with complementa
175 symptom (i.e. the seizures) rather than the underlying disease process (i.e. epileptogenesis).
176 use can be tailored to individual patients' underlying disease process and need for neuroprotective
177 nsplanted PD patients further shows that the underlying disease process does not destroy transplanted
178 is emphasizes the critical importance of the underlying disease process for macrophage functional dev
179 ifferent HDM-LD changes, suggesting that the underlying disease process in the contralateral hippocam
180 The underlying disease process is the major determinant of o
181 ease from pulmonary disease secondary to the underlying disease process of rheumatoid arthritis.
182 We identified biomarkers relevant to the underlying disease process progression and response to t
183 trate on novel and safe ways to modulate the underlying disease process rather than stopping excess t
184 nsive to conventional ventilation and if the underlying disease process was deemed reversible.
185 multiple organ failure associated with their underlying disease process, and 96% of the remaining 120
186 branous nephropathy and thus suggest another underlying disease process, such as combined membranous
187 opathy may not always accurately reflect the underlying disease process.
188 biologic mechanisms that are involved in the underlying disease process.
189 generally be alleviated by correction of the underlying disease process.
190 ardiovascular disease, or simply reflect the underlying disease process.
191 le in critical illness is influenced by both underlying disease processes and the intensive care envi
192 HCM and DCM, noncontrast T1 mapping detects underlying disease processes beyond those assessed by LG
193 t in RDP holds promise for understanding the underlying disease processes of both of these more commo
194 omen and in other patients that have chronic underlying disease processes.
195 ed to understand the pathological mechanisms underlying disease processes.
196 may slow cognitive decline but do not alter underlying disease processes.
197 ntial to illuminate the molecular mechanisms underlying disease progression and response to treatment
198 offer new insights into the molecular events underlying disease progression.
199 ian cancer, potentially affecting many genes underlying disease progression.
200 The Pramipexole On Underlying Disease (PROUD) study was designed to identif
201 is the cause of respiratory failure and the underlying disease, rather than duration of ventilatory
202 Management of the underlying disease, recognizing and preventing disease p
203 transplantation occur in the first year, but underlying disease renders these patients susceptible to
204 o investigate the complex signaling networks underlying disease resistance in Arabidopsis.
205 In all cases, the underlying disease responded well to rituximab.
206 In patients with potentially reversible underlying diseases resulting in severe acute respirator
207 rough the investigation of individual traits underlying disease risk.
208 However, mechanisms underlying disease severity and virulence in arenavirus
209 Although underlying disease severity could also play a role, avoi
210 Physician appraisal of underlying disease severity is potentially vulnerable to
211 Chronic outcome predictors included the underlying disease severity, application of novel techno
212 icult to establish because of confounding by underlying diseases, severity of infection, and differen
213 between clinicians identifying and treating underlying disease, specialist ophthalmic review, and op
214 status and more accurate assessments of the underlying disease state and response to treatment, thus
215 he indication for their removal has not been underlying disease states in those organs.
216 ophin signaling may play a role in processes underlying disease states such as schizophrenia, Alzheim
217 the retina may sustain injury as a result of underlying disease such as diabetes, and/or the interact
218 atients with normal hearts and in those with underlying disease such as heart failure.
219 in may contribute to metabolic dysregulation underlying diseases, such as obesity and type 2 diabetes
220 al posterior medial temporal lobe due to the underlying disease, suggesting that it is the capacity o
221 ndings provide a novel molecular explanation underlying disease susceptibility associated with COX-2
222 t, for the majority of these, the mechanisms underlying disease susceptibility remain unknown.
223 nt data defining the common genetic variants underlying disease susceptibility, and explore how impro
224 ication and description of genetic variation underlying disease susceptibility, efficacy, and adverse
225 de the identification of regulatory variants underlying disease susceptibility.
226 han simply being a marker of the severity of underlying disease, the adequacy of renal function may b
227 of these parameters include patient status (underlying disease, the presence of intravascular cathet
228 need to take into account the nature of the underlying disease, the severity of the nephrotic syndro
229 n the absence of effective treatment for the underlying disease, therapeutic options are limited to t
230 s often provide estimates of the severity of underlying disease to aid patients and families when for
231 neutropenia as the sole abnormality, with no underlying disease to which the neutropenia can be attri
232 Success in reconstructing gene networks underlying disease traits (or other complex traits like
233 Risk factors included host variables (age, underlying disease), transplant variables (stem cell sou
234 ssociated with the neuropathological effects underlying disease-, trauma- and chemically induced neur
235 Covariables in addition to gB type included underlying disease type, donor-recipient HLA matching, d
236 use, whereas univariate analysis identified underlying disease, type of operation, and high levels o
237 No underlying disease was discovered during prolonged follo
238 hen treatment directed toward control of her underlying disease was only partially effective, further
239 The main underlying diseases were acute leukemia (35.7%), lymphom
240 rted series, but bleeding manifestations and underlying diseases were similar.
241 Major underlying diseases were solid organ transplantation (24
242 S, presence or absence of documented sepsis, underlying disease, whether or not there was a do-not-re
243 stay was 40% longer for individuals with an underlying disease with a genetic basis than for those w
244 l is seen despite the SLE patients having an underlying disease with multiorgan involvement and despi
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。